Taken together, our study provided key evidences that management of female infertility with Cai’s Prescription was beneficial for poor ovarian responders, leading to increase of the number of high quality embryos, and ARHGAP4 may be a candidate target for POR treatment. This evidence concerns the gene ARHGAP4 and female infertility.